Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Trabectedin is an established treatment for advanced soft tissue sarcomas (STSs).
• The potential of combining trabectedin with irradiation (IR) to improve STS treatment outcomes requires further investigation.

Purpose of the Study:

• To evaluate trabectedin's ability to enhance the efficacy of IR in various STS cell lines.
• To assess trabectedin's impact on cell radiosensitivity, invasiveness, cell cycle, and DNA damage response in combination with IR.

Main Methods:

• Trabectedin and IR combination therapy was tested on fibrosarcoma, leiomyosarcoma, liposarcoma, and rhabdomyosarcoma cell lines.
• Cell surviving fraction (SF), invasiveness, cell cycle distribution, and γ-H2AX foci formation were analyzed.
• Expression levels of DNA repair proteins, angiogenesis factors, and immune markers were assessed.

Main Results:

• Trabectedin significantly reduced cell SF in liposarcoma and leiomyosarcoma when combined with IR, showing radiosensitizing effects.
• Combined therapy decreased invasive cell fraction and altered cell cycle distribution in specific STS types.
• Elevated γ-H2AX foci indicated increased DNA damage in all STS lines treated with trabectedin + IR.

Conclusions:

• Trabectedin demonstrates radiosensitizing potential in STS, notably enhancing IR efficacy in liposarcoma and leiomyosarcoma.
• The combination impacts cell survival, invasiveness, and DNA damage, but not DNA repair, angiogenesis, or immune response synergistically.